Analyst picks & changes

Amgen Inc.


Merrill Lynch analyst Jeffrey Casdin raised his 1995 EPS estimate on the Thousand Oaks, Calif., company to $3.75 from $3.70. He noted that


erythropoietin is continuing its growth spurt and that


Read the full 387 word article

How to gain access

Continue reading with a
two-week free trial.